A phase II study of chemoselection with docetaxel, cisplatin, and 5–fluorouracil as a strategy for organ preservation in patients with resectable esophageal cancer (CROC trial).

Chikatoshi Katada,Hiroki Hara,Hirofumi Fujii,Takako Eguchi Nakajima,Takayuki Ando,Motoo Nomura,Takashi Kojima,Keishi Yamashita,Tetsuji Yokoyama,Yasutoshi Sakamoto,Hiroki Sasaki,Yusuke Inoue,Shogo Kawakami,Hideki Ishikawa,Ayumu Hosokawa,Yasuo Hamamoto,Manabu Muto,Makoto Tahara,Wasaburo Koizumi

A phase II study of chemoselection with docetaxel, cisplatin, and 5–fluorouracil as a strategy for organ preservation in patients with resectable esophageal cancer (CROC trial).

2021

Chikatoshi Katada
Hiroki Hara
Hirofumi Fujii
Takako Eguchi Nakajima
Takayuki Ando
Motoo Nomura
Takashi Kojima
Keishi Yamashita
Tetsuji Yokoyama
Yasutoshi Sakamoto
Hiroki Sasaki
Yusuke Inoue
Shogo Kawakami
Hideki Ishikawa
Ayumu Hosokawa
Yasuo Hamamoto
Manabu Muto
Makoto Tahara
Wasaburo Koizumi

4027Background: In patients with resectable esophageal squamous cell carcinoma (SCC), the outcomes of chemoradiotherapy (CRT) for good responders after three courses of induction chemotherapy (IC) ...

Keywords:

Docetaxel
Internal medicine
Fluorouracil
Chemoradiotherapy
Medicine
in patient
Oncology
Phases of clinical research
Esophageal cancer
Cisplatin
Induction chemotherapy

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations